NSG
PACB icon

Nalls Sherbakoff Group’s Pacific Biosciences PACB Stock Holding History

Nalls Sherbakoff Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
16
– – ﹤0.01% 374
2026
Q1 		$21 Hold
16
– – ﹤0.01% 410
2025
Q4 		$30 Hold
16
– – ﹤0.01% 441
2025
Q3 		$20 Hold
16
– – ﹤0.01% 425
2025
Q2 		$20 Sell
16
-18
-53% -$21 ﹤0.01% 428
2025
Q1 		$40 Buy
+34
New +$52 ﹤0.01% 434
2023
Q4 		$334 Hold
34
– – ﹤0.01% 432
2023
Q3 		$284 Hold
34
– – ﹤0.01% 445
2023
Q2 		$421 Hold
34
– – ﹤0.01% 459
2023
Q1 		$332 Buy
+34
New +$338 ﹤0.01% 493

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nalls Sherbakoff Group's PACB Position: Q2 2026 in Review

Nalls Sherbakoff Group held its Pacific Biosciences (PACB) position steady in Q2 2026 at 16 shares worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #374.

Nalls Sherbakoff Group first reported a position in PACB in Q1 2023 and has held it in 10 quarters since. The position peaked at $421 in Q2 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Nalls Sherbakoff Group held 16 shares of Pacific Biosciences worth $27 as of Q2 2026.
  • Nalls Sherbakoff Group left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #374 holding.
  • Nalls Sherbakoff Group first reported a position in Pacific Biosciences in Q1 2023 and has held it in 10 quarters since.
  • Nalls Sherbakoff Group's Pacific Biosciences position peaked at $421 in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.